Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.31 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 5 Parkinson's papers of 2,343 | 0.76 |
| pathways Reactome | 3 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 1237
Sealed predictions
- CALU in dopamine neurons, braak+0.16 (p 0.685) → +0.47 (p 0.197)receipt 1242
Swarm cases
receipt 1242: CALU in dopamine neurons, braak
- power
- full sample +0.25 (p 0.319, n 18), 95% CI -0.25 to +0.64. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.25 (p 0.319, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.29 (p 0.250, n 18). could be the mix.
- skeptic
- leave-one-out range +0.18 to +0.45, sign flips 0; without severely affected donors +0.25 (p 0.319, n 18). fragile.
- cell type
- strongest in astrocytes: -0.60 (p 0.0080, n 18) vs +0.25 in dopamine neurons. proposing astrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CALU in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up CALU · astrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.32 p 0.248 (needs p < 0.0011)
Receipts
loading the receipts